TriLink BioTechnologies, Quantoom Biosciences sign license, supply agreement

TriLink BioTechnologies signed a non-exclusive License and Supply Agreement with Quantoom Biosciences. Under the agreement, Quantoom will have access to TriLink’s CleanCap mRNA capping technology for integration in its Ntensify mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide. TriLink’s CleanCap technology produces optimal 5 cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom’s mRNA production platform, allowing customers to benefit from the industry’s leading capping technology to develop their unique mRNA drugs using the Ntensify platform through clinical development phases.